U.S. Senate Committee exposes Big Pharma medical fraud

The U.S. Senate Committee on Finance investigated the diabetes drug Avandia and its manufacturer GlaxoSmithKline. A report was published in January 2010. It comprises of 342 pages, hence it took me some time to study it all.

The report can be purchased from the Superintendent of Documents, U.S. Government Printing Office (full details via link?below).

The findings of this report, based on a most thorough investigation spanning two years,?are important for public health?to say the least. I therefore take the liberty to post the 18 most significant pages here: US Senate Committee Report January 2010.

What we can learn from this report:

1. “Scientific research results” are NOT “Scientific research results”. The script is written by Big Pharma and scientists serve as willing tools to produce the desired result.

2. The investigated diabetes drug Avandia may be the worst of the lot, but all cause heart attacks instead of preventing them as the public is made to believe. Avandia increases death from heart attacks by 43%. This means that 43 out of 143 diabetes patients that?die from heart attack do so because they are on Avandia. Relate this figure to the millions who take Avandia and you get a graveyard of a respectable size.

3. Behaviour and actions of GlaxoSmithKline, their executives and scientists to be exact, are the norm in Big Pharma and constitute an Industry Standard. This includes?but is not limited to intimidation of unwilling scientists, deception of regulating bodies, falsification and supression of evidence. Getting caught is a calculated risk. This is reflected in the fact that?”The Industry” paid fines and penalties of some $7billion since 2004 in the U.S. alone.

The report reads like a James Bond 007 script, enjoy reading. http://infoholix.net/article_US-Senate-Committee-report-January2010.php



Wilfrid Hartnagel
ceo, infoholix.net

Reprint of web pages are only allowed with explicit permission. Please request our permission by emailing us with a complete description of the intended use.

This entry was posted in iHN Archive, Medical Tsunami N°1. Bookmark the permalink.